Next Article in Journal / Special Issue
Core as a Novel Viral Target for Hepatitis C Drugs
Previous Article in Journal
Dendritic Cells and HIV-1 Trans-Infection
Previous Article in Special Issue
Possibilities for RNA Interference in Developing Hepatitis C Virus Therapeutics
Viruses 2010, 2(8), 1718-1733; doi:10.3390/v2081718
Review

Targeting HCV Entry For Development of Therapeutics

* ,
 and
Received: 28 June 2010; in revised form: 5 August 2010 / Accepted: 16 August 2010 / Published: 18 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
View Full-Text   |   Download PDF [182 KB, uploaded 18 August 2010]   |   Browse Figure
Abstract: Recent progress in defining the molecular mechanisms of Hepatitis C Virus (HCV) entry affords the opportunity to exploit new viral and host targets for therapeutic intervention. Entry inhibitors would limit the expansion of the infected cell reservoir, and would complement the many replication inhibitors now under development. The current model for the pathway of entry involves the initial docking of the virus onto the cell surface through interactions of virion envelope and associated low density lipoproteins (LDL) with cell surface glycosaminoglycans and lipoprotein receptors, followed by more specific utilization with other hepatocyte membrane proteins: Scavenger Receptor Class B type 1 (SR-BI), CD81, Claudin 1 (CLDN1) and Occludin (OCLN). The use of blockers of these interactions, e.g. specific antibodies, suggests that inhibition of any one step in the entry pathway can inhibit infection. Despite this knowledge base, the tools for compound screening, HCV pseudoparticles (HCVpp) and cell culture virus (HCVcc), and the ability to adapt them to industrial use are only recently available and as a result drug discovery initiatives are in their infancy. Several therapies aiming at modulating the virus envelope to prevent host cell binding are in early clinical testing. The first test case for blocking a cellular co-receptor is an SR-BI modulator. ITX 5061, an orally active small molecule, targets SR-BI and has shown potent antiviral activity against HCVpp and HCVcc. ITX 5061 has exhibited good safety in previous clinical studies, and is being evaluated in the clinic in chronic HCV patients and patients undergoing liver transplantation. Entry inhibitors promise to be valuable players in the future development of curative therapy against HCV.
Keywords: HCV entry inhibitors; SR-BI; HCVpp; therapeutics development HCV entry inhibitors; SR-BI; HCVpp; therapeutics development
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wong-Staal, F.; Syder, A.J.; McKelvy, J.F. Targeting HCV Entry For Development of Therapeutics. Viruses 2010, 2, 1718-1733.

AMA Style

Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV Entry For Development of Therapeutics. Viruses. 2010; 2(8):1718-1733.

Chicago/Turabian Style

Wong-Staal, Flossie; Syder, Andrew J.; McKelvy, Jeffrey F. 2010. "Targeting HCV Entry For Development of Therapeutics." Viruses 2, no. 8: 1718-1733.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert